{"id":383735,"date":"2020-11-18T07:03:14","date_gmt":"2020-11-18T12:03:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383735"},"modified":"2020-11-18T07:03:14","modified_gmt":"2020-11-18T12:03:14","slug":"g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/","title":{"rendered":"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">RESEARCH TRIANGLE PARK, N.C., Nov.  18, 2020  (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4Z7jetHwKonBHXFgv8TSGqjVHO3RMwVyhpdk0vNawf24J4mEMkQweCw5WrR_UOVuWIG17d-k-9m5Sr4h1Sw17Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">GTHX<\/a>), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine\/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.<\/p>\n<p>The company will also present updated monotherapy findings from the Phase 1 portion of its ongoing clinical trial of rintodestrant, a potential best-in-class oral selective estrogen receptor degrader (SERD) in development for treatment of ER+, HER2- breast cancer.<\/p>\n<p>\u201cThe findings in the triple-negative breast cancer trial support our strategy to continue to evaluate the potential of trilaciclib to enhance the anti-tumor efficacy of chemotherapy,\u201d said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&amp;D. \u201cWe expect to initiate a pivotal trial of trilaciclib in metastatic TNBC in 2021 with overall survival as the primary endpoint, and will provide additional details on the trial during the 2020 SABCS.\u201d<\/p>\n<p>Information on G1 presentations at 2020 SABCS follows below; additional details are available on the SABCS <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A7YaeJYtz_tBsm8UUkW9_j8WFZVIw98pUWGZaRXF2RcL0RxMFgzFJp_gk65SWrYmS8Typ24QrJue5e3S335Y9Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">website<\/a>.<\/p>\n<p>Title: Trilaciclib improves overall survival when given with gemcitabine\/carboplatin in patients with metastatic triple-negative breast cancer: final analysis of a randomized Phase 2 trial<br \/>Presenter: Joyce O\u2019Shaughnessy, M.D., Baylor University Medical Center<br \/>Poster #PD1-06:Spotlight Poster Discussion 1<br \/>Date\/time: Wednesday, December 9, 2020; 4:00\u20135:15 p.m. CT<\/p>\n<p>Title: Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+\/HER2- locally advanced or metastatic breast cancer: updated Phase 1 results and dose selection <br \/>Presenter: Philippe Aftimos, M.D., Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles<br \/>Poster #PS12-04: Poster Session 12<br \/>Date\/time: Wednesday, December 9, 2020; 8:00 a.m. CT<\/p>\n<p>Title: Pharmacodynamic analysis from a Phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+\/HER2\u2013 locally advanced or metastatic breast cancer <br \/>Presenter: Philippe Aftimos, M.D., Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles<br \/>Poster #PD8-07: Spotlight Poster Discussion 8<br \/>Date\/time: Thursday, December 10, 2020; 2:15\u20133:30 p.m. CT<\/p>\n<p>Title: Population pharmacokinetic and exposure-response modeling of the oral selective estrogen receptor degrader rintodestrant (G1T48) in patients with ER+\/HER2\u2013 advanced breast cancer<br \/>Presenter: Chao Li, Ph.D., G1 Therapeutics, Inc.<br \/>Poster #PS17-08: Poster Session 17<br \/>Time\/date: Wednesday, December 9, 2020; 8:00 a.m. CT<\/p>\n<p>\n        <strong>About G1 Therapeutics<\/strong><br \/>\n        <br \/>G1 Therapeutics, Inc.\u00a0is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=csPCsUqiM6KL7wYmRxkqI3hTSqT0hDo1Ofr7BgT9HMeNfxry67_egKjSaYD6XNV5BZZGFqA4J9NlzOYnmyUxqF29TVCdQmTC3Iq-HXrlNY6NTTIHqsGPBh31Z8UN5s-f\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">trilaciclib<\/a> is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9qlrcnnvwkQOMACl4G6ZRtVhvBHZBVf1zXLWdOy1AADA71VPCel6CxzyJz1oXCMmXB88uWy5UetAjhEtuoKXA2aYrWn5T9KOAT1x2km6abKsL2UHHjLF2pSZ3-RaxW6A\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rintodestrant<\/a> is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4\/6 inhibitor, lerociclib.<\/p>\n<p>G1 Therapeutics\u00a0is based in\u00a0Research Triangle Park, N.C.\u00a0For additional information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J5UBjIdRHf3RVVWCDI1keDks7SkgIwtVkFuU3pyFLuvLGtPoLPbE643dRAyMPZ7hB7TWZECWVvXNmDQET2OYjSlKDg2XxiykDc91bVERENs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.g1therapeutics.com<\/a>\u00a0and follow us on Twitter\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c1dO1OauJuPlLG_ejqMcdGbeqxVGDstrfKWR-I8Cl1MZ6vlCS5skij7SHnGnBJrP4TeG6KMBuQ-dE-kLxC8lLEQOGcgzhKHwyBk5D5aPZrJHlp_CpHuCuJXj36ONdCSlm1d2BnRx-VKdO4qp-7YmSot9P8_EZ4bZ1HQeQQFCHF_fvSQ0-UjBxRyRZgm5RWyg5HW7kYEGN2c-JI-7zxlQEjlynyiP2Vnb8E4BYGAOZCJDk7WImG3MfpqMkjQj4Oie\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">@G1Therapeutics<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in the U.S. and Europe for trilaciclib in SCLC, trilaciclib\u2019s possibility to improve patient outcomes across multiple indications, rintodestrant\u2019s potential to be best-in-class oral SERD, lerociclib\u2019s differentiated safety and tolerability profile over other marketed CDK4\/6 inhibitors, our reliance on partners to develop and commercial licensed products, and the impact of pandemics such as COVID-19 (coronavirus), are based on the company\u2019s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the company\u2019s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the &#8220;Risk Factors&#8221; sections contained therein and include, but are not limited to, the company\u2019s ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the company\u2019s initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Jeff Macdonald<br \/>G1 Therapeutics, Inc.<br \/>Senior Director, Investor Relations &amp; Corporate Communications<br \/>919-907-1944<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KdJr_2jgvGFsapoiBudB0V4rXHnkpdayTKr87d13LAYV0d55ssbCsCWg66QZc30TYNNsu2YcTyYUcQAroJUMBVde0rpputf_jvNGHHyHWjlCuglEHhr6t1rV5UW5tvza\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jmacdonald@g1therapeutics.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d496f3fe-10b9-4adc-a319-f574fae2ad2d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine\/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. The company will also present updated monotherapy findings from the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383735","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine\/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. The company will also present updated monotherapy findings from the &hellip; Continue reading &quot;G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-18T12:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)\",\"datePublished\":\"2020-11-18T12:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/\"},\"wordCount\":880,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/\",\"name\":\"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=\",\"datePublished\":\"2020-11-18T12:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/","og_locale":"en_US","og_type":"article","og_title":"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS) - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine\/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. The company will also present updated monotherapy findings from the &hellip; Continue reading \"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-18T12:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)","datePublished":"2020-11-18T12:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/"},"wordCount":880,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/","name":"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=","datePublished":"2020-11-18T12:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODEwNyMzODMyNTUxIzIwMjkxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-present-clinical-data-on-trilaciclib-and-rintodestrant-at-2020-san-antonio-breast-cancer-symposium-sabcs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383735"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}